October 26, 2017
…and physicians at Moores Cancer Center at UC San Diego Health, in partnership with colleagues at MD Anderson Cancer Center in Texas, Johns Hopkins University in Maryland and elsewhere, have been awarded a $7 million grant over four years by Stand Up to Cancer (SU2C) to create a “dream team”…
November 20, 2018
A team of University of California San Diego School of Medicine researchers have been awarded a $1 million Stand Up To Cancer (SU2C) grant to test drugs that block signals that play a critical role in driving growth and progression of pancreatic cancer.
November 29, 2018
Moores Cancer Center at UC San Diego Health launched the Pancreatic Cancer Prevention and Screening Clinic in an attempt to reduce the number of people who develop the disease and improve survival for those who do. Every day in the U.S., 145 people are diagnosed and every 12 minutes someone…
January 8, 2024
Diana M. Simeone, MD, has been named the new director of Moores Cancer Center at UC San Diego Health.
September 3, 2015
In some patients, aggressive cancers can become resistant to chemotherapy and radiation treatments. In a paper published in the journal Nature Communications, University of California, San Diego School of Medicine researchers identified a pathway that causes the resistance and a new therapeutic drug that targets this pathway.
May 15, 2012
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention.
March 18, 2021
Researchers at UC San Diego School of Medicine and Moores Cancer Center describe how pancreatic cancer cells use an alternative method to find necessary nutrients, defying current therapies, to help them grow and spread.
October 4, 2016
Physician-scientists with Moores Cancer Center at UC San Diego Health have been leading the way in pancreatic cancer care by investigating new therapies as well as offering innovative clinical trials and the latest treatments with a personalized medicine approach. This expertise led to the selection of Moores Cancer Center as…
June 6, 2016
Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. In a new study, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University, the University of Nebraska and…
March 20, 2019
…clinicians to potentially one day use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.
